

Applicants : Michael J. Elliott et al.
Serial No. : 08/602,272
Filed : February 16, 1996
Page 3 of 13 of October 6, 2008 Supplemental Amendment As A
Submission Under 37 C.F.R. § 1.114(c)

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-5. (Canceled)

6. (Currently Amended) A method of treating a thrombotic disorder in an individual in need thereof comprising administering a therapeutically effective amount of an anti-human tumor necrosis factor- α alpha monoclonal antibody or antigen-binding fragment thereof to the individual, wherein the thrombotic disorder is selected from the group consisting of: a thromboembolic disorder, an ischemic event, stroke, acute myocardial infarction, deep vein thrombosis and thrombophlebitis.

7-8. (Canceled)

9. (Currently Amended) The method of claim 6, wherein the monoclonal antibody is selected from the group consisting of a humanized antibody or antigen-binding fragment thereof and a resurfaced antibody or antigen-binding fragment thereof.

10. (Currently Amended) The method of claim 6, wherein the monoclonal antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α human tumor necrosis factor- α .

Applicants : Michael J. Elliott et al.
Serial No. : 08/602,272
Filed : February 16, 1996
Page 4 of 13 of October 6, 2008 Supplemental Amendment As A
Submission Under 37 C.F.R. § 1.114(c)

11. (Canceled)
12. (Currently Amended) The method of claim 6, wherein the monoclonal antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNFtumor necrosis factor or an antigen-binding portion thereof and (b) a human constant region.
13. (Currently Amended) The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNFhuman tumor necrosis factor- α .
14. (Previously Presented) The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.
15. (Currently Amended) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNFatumor necrosis factor- α to monoclonal antibody cA2.
- 16-50. (Canceled)
51. (Currently Amended) A method of treating a thrombotic disorder in an individual in need thereof comprising administering a therapeutically effective amount of an anti-human tumor necrosis factor- α alpha—monoclonal antibody or antigen-binding fragment thereof to the individual, wherein the thrombotic disorder is deep vein thrombosis.

Applicants : Michael J. Elliott et al.
Serial No. : 08/602,272
Filed : February 16, 1996
Page 5 of 13 of October 6, 2008 Supplemental Amendment As A
Submission Under 37 C.F.R. § 1.114(c)

52. (Canceled)

53. (Currently Amended) The method of claim 6, wherein the thrombotic disorder is acute myocardial infarction, deep vein thrombosis or thrombophlebitis.